viruses news - the latest biotech news from Labiotech.eu

Swedish researchers look to peptides to destroy viruses

Jim Cornall — Fri, 07 Jul 2023 08:41:11 +0000

A new study from Sweden shows how a type of peptide from a lactic acid bacterium destroys viruses, including coronavirus. The findings have resulted in a Swedish patent, with an international patent pending. “We’re hoping for a quick turnaround to allow this discovery to be utilised in antiviral treatments and as a complement to vaccine,” […]

The post Swedish researchers look to peptides to destroy viruses appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Virus tracking could be key to kidney transplant patients’ drug choices

External Contributor — Fri, 30 Jun 2023 08:32:49 +0000

By Dr Gregor Bond More than 15,000 Europeans undergo kidney transplants on average each year, and while medical advances have helped many recipients enjoy healthy lives, the risks of organ rejection and infection remain huge challenges. With each transplant, success depends on using carefully balanced doses of immuno-suppressive drugs to reduce the risk of infection […]

The post Virus tracking could be key to kidney transplant patients’ drug choices appeared first on Labiotech.eu.

Delivering on the need for vector innovation in genetic medicine

External Contributor — Wed, 10 May 2023 07:30:00 +0000

By Tuyen Ong, CEO Ring Therapeutics, CEO-Partner Flagship Pioneering Gene therapy is a life-changing class of medicine that can treat patients with once intractable diseases. While revolutionary, significant limitations remain for the vectors that carry them. Viruses are masters at delivering genetic material to the nucleus of the organisms they infect, and because of this, […]

The post Delivering on the need for vector innovation in genetic medicine appeared first on Labiotech.eu.

FDA fast track for Memo’s kidney transplant infection treatment

Jim Cornall — Tue, 02 May 2023 10:41:47 +0000

Memo Therapeutics AG, a biotech company developing therapeutic antibodies, says the U.S. Food and Drug Administration (FDA) has granted fast track designation to AntiBKV, Memo Therapeutics’ lead antibody therapeutic that targets BK polyomavirus (BKV) infection commonly seen in renal transplant patients. AntiBKV has successfully completed a phase I clinical study and following FDA clearance has […]

The post FDA fast track for Memo’s kidney transplant infection treatment appeared first on Labiotech.eu.

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Jim Cornall — Wed, 21 Dec 2022 11:04:30 +0000

Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. The collaboration is founded on a $42 million award to DIOSynVax by the […]

The post Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine appeared first on Labiotech.eu.

TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses

Jim Cornall — Wed, 07 Sep 2022 12:20:24 +0000

TikoMed has announced the inclusion in bioRxiv of an in vitro study examining the ability of the company’s lead drug candidate ILB to inhibit infection of human cells by four serotypes of dengue virus (DENV1-4), two strains of zika virus (African and Asian) and yellow fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral […]

The post TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses appeared first on Labiotech.eu.

Gannex’ first patient dosed in study for treatment of primary biliary cholangitis

Liza Laws — Tue, 16 Aug 2022 12:34:07 +0000

A study looking at a treatment for primary biliary cholangitis (PBC) has this month (August) enrolled 12 patients and is expected to be completed by the start of this year’s fourth quarter. Gannex Pharma Co., Ltd., owned by Ascletis Pharma Inc., announced yesterday (August 15) that it had finished its first dosing in the […]

The post Gannex’ first patient dosed in study for treatment of primary biliary cholangitis appeared first on Labiotech.eu.

Stem cell therapy to be used in treatment of long COVID by Panacell Biotech

Liza Laws — Wed, 10 Aug 2022 16:14:02 +0000

A South Korean biotech company says it will use natural killer (NK) cells, exosomes and brown adipose-derived stem cells (ADSC) as treatment of long COVID. NK cells are a type of immune cell that have granules or small particles that can kill tumor cells or those infected with a virus. Panacell Biotech said they can […]

The post Stem cell therapy to be used in treatment of long COVID by Panacell Biotech appeared first on Labiotech.eu.

Rensselaer researchers make face masks to fight viruses

Jim Cornall — Wed, 22 Jun 2022 14:50:53 +0000

Researchers at Rensselaer Polytechnic Institute in Troy, NY, have developed N95 surgical face masks that are not just barriers to bacteria and viruses, but can also destroy them. The team said the antiviral, antibacterial masks can be worn for longer, creating less waste as the masks do not need to be replaced as frequently. Helen […]

The post Rensselaer researchers make face masks to fight viruses appeared first on Labiotech.eu.